基于转录组特征预测胰腺腺癌辅助吉西他滨敏感性
研究利用PaCaOmics项目来源的临床前模型建立GemPred RNA签名,在67例和368例切除PDAC回顾性队列中验证。在吉西他滨治疗患者中,GemPred+者OS显著优于GemPred-(91.3个月 vs 33个月,HR 0.403,P=0.00216),且治疗交互作用显著。
要点
- GemPred+预测吉西他滨辅助治疗获益,GemPred-者OS显著较差。
- 未接受吉西他滨者中GemPred分层与OS无关,提示预测性而非预后性。
- 交互作用检验支持GemPred对吉西他滨疗效的预测价值。
核心结论
- 基于RNA的GemPred分层可预测PDAC患者辅助吉西他滨的获益。
研究设计与样本
- 利用PaCaOmics项目来源的原代细胞培养和患者来源异种移植模型进行化疗敏感性与全基因组RNA谱检测。
- 在单中心67例和多中心368例回顾性切除PDAC样本队列中测试和验证RNA分层。
主要发现
- 在测试和验证队列的吉西他滨治疗患者中,GemPred+者OS高于GemPred-(P=0.046和P=0.00216)。
- 两队列中未接受吉西他滨者GemPred分层与OS无关。
- 吉西他滨治疗患者中GemPred+者OS为91.3个月(95%CI 61.2-未达到),GemPred-者为33个月(95%CI 24-35.2),HR 0.403(95%CI 0.221-0.735,P=0.00216)。
- 吉西他滨与GemPred+分层的交互作用检验显著(P=0.0245)。
- 吉西他滨治疗人群多变量分析中GemPred保留独立预测价值。
临床怎么用
- GemPred分层或可辅助筛选辅助吉西他滨可能获益的PDAC患者。
局限性
- 验证队列为回顾性收集的切除PDAC样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments. PATIENTS AND METHODS: Concomitant chemosensitivity and genome-wide RNA profiles were carried out on preclinical models (primary cell cultures and patient-derived xenografts) derived from patients with PDAC included in the PaCaOmics program (NCT01692873). The RNA-based stratification was tested in a monocentric cohort and validated in a multicentric cohort, both retrospectively collected from resected PDAC samples (67 and 368 patients, respectively). Forty-three (65%) and 203 (55%) patients received adjuvant gemcitabine in the monocentric and the multicentric cohorts, respectively. The relationships between predicted gemcitabine sensitivity and patients' overall survival (OS) and disease-free survival were investigated. RESULTS: The GemPred RNA signature was derived from preclinical models, defining gemcitabine sensitive PDAC as GemPred+. Among the patients who received gemcitabine in the test and validation cohorts, the GemPred+ patients had a higher OS than GemPred- (P = 0.046 and P = 0.00216). In both cohorts, the GemPred stratification was not associated with OS among patients who did not receive gemcitabine. Among gemcitabine-treated patients, GemPred+ patients had significantly higher OS than the GemPred-: 91.3 months [95% confidence interval (CI): 61.2-not reached] versus 33 months (95% CI: 24-35.2); hazard ratio 0.403 (95% CI: 0.221-0.735, P = 0.00216). The interaction test for gemcitabine and GemPred+ stratification was significant (P = 0.0245). Multivariate analysis in the gemcitabine-treated population retained an independent predictive value. CONCLUSION: The RNA-based GemPred stratification predicts the benefit of adjuvant gemcitabine in PDAC patients.
引用
- Nicolle R, Gayet O, Duconseil P, et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Ann Oncol. 2020. PMID: 33188873. doi:10.1016/j.annonc.2020.10.601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。